A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
Brent A. Williams(Mayo Clinic), Armand Keating(University Health Network), Bertrand Routy(Centre Hospitalier de l’Université de Montréal), Arjun Law(University of Toronto), Vikas Gupta(Indian Institute of Technology Kanpur), A. Chaboureau(Princess Margaret Cancer Centre), Neal denHollander(University Health Network), Xinghua Wang(Princess Margaret Cancer Centre), Sowmya Viswanathan(University Health Network)
Cited by 187
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
|Science|2020|382